2021 Annual Business Report

Our strategy

Valneva aims to become a highly valued, internationally known vaccine company focusing on products that can make a difference in people’s lives.


Our strategy

A specialty vaccine company

Valneva focuses on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need.

As such, our business model integrates the whole value chain, from research to commercialization.

Valneva takes a highly specialized and targeted approach to the development of unique prophylactic vaccines.

This has led to an advanced pipeline of differentiated clinical-stage assets designed to address large target populations.

Valneva’s R&D has been validated by strategic partnerships and the Company plans to continue pursuing partnering or stand-alone opportunities in the future.